HIV vaccine progress made
Nabs are immune proteins that bind to and provoke the destruction of a virus before it develops into a chronic infection. It is crucial that an HIV/AIDS vaccine provokes a strong Nab response in order to protect the patient against a variety of HIV subtypes, as well as a variety of infections.
Provoking a broad and strong Nab response can be partially controlled by polyclonal antibodies that would target several different antigenic targets or epitopes within a virus.
One of the published studies suggests that a repertoire of Nab can start after a superinfection. The second published study evaluates the effectiveness of using Nabs to interrupt direct cell-to-cell transmission of the HIV infection, which would stop the infection before it developed any further.
"Eliciting a highly diverse immune response may be favorable to providing protection against incredibly diverse HIV-1 variants in global circulation supports further investigations of the molecular and functional characteristics of the virus-antibody interplay in superinfected individuals, as superinfection may provide insight to the development of a diverse Nab response with multiple epitope specificities,” researchers from the Fred Hutchison Cancer Research Center in Seattle said.